In our analysis, we incorporated data from 22 RCTs that compared the risk of CIP associated with PD-1/PD-L1 or CTLA-4 inhibitor use alone or in combination with chemotherapy. This evidence concerns the gene PDCD1 and hereditary sensory and autonomic neuropathy.